Stockscreener 앱 받기
8.07
3.73%
0.29
시간 외 거래:
8.01
-0.06
-0.74%
Minerva Neurosciences Inc 주식(NERV)의 최신 뉴스
HC Wainwright Has Bullish Forecast for NERV Q1 Earnings - MarketBeat
Minerva Neurosciences shareholders approve key governance measures - MSN
What is HC Wainwright's Forecast for NERV Q1 Earnings? - MarketBeat
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum - Investing News Network
NERV: HC Wainwright & Co. Raises Price Target to $7.00, Maintains Neutral Rating | NERV Stock News - GuruFocus
H.C. Wainwright raises Minerva Neurosciences price target on trial design By Investing.com - Investing.com Canada
CNS therapies firm Minerva joins Stifel 2026 virtual forum webcast - Stock Titan
Minerva Neurosciences: Q4 Earnings Snapshot - theheraldreview.com
Minerva Neurosciences (NERV) Advances Toward Phase 3 Trial with FDA Support - GuruFocus
Minerva Neurosciences Announces $80M Financing and Plans Phase 3 Trial for Roluperidone in Schizophrenia with Results Expected 2H 2027 - Minichart
Minerva Neurosciences (NASDAQ:NERV) Issues Quarterly Earnings Results - MarketBeat
Minerva Neurosciences (NERV) registers $200M shelf for stock, debt and warrants - Stock Titan
Minerva Neurosciences, Inc (NERV) Reports Q4 Earnings - AlphaStreet
Minerva Neurosciences: Fourth Quarter Financial Overview - Bitget
Minerva Neurosciences Q4 & 2025 Financials: Annual Loss of $293.4MNews and Statistics - IndexBox
Minerva Neurosciences 10-K: Revenue $0, EPS (34.67) on large net loss - TradingView
Minerva Neurosciences Q4 net loss widens on non-cash financing charges - TradingView
Minerva Neurosciences Reports $283.7M Q4 Net Loss; $82.4M Cash at Year-End - TradingView
Minerva Neurosciences Reports Q4 and Full-Year 2025 Financial Results and Updates on Roluperidone Development for Schizophrenia Treatment - Quiver Quantitative
BRIEF-Minerva Neurosciences Q4 Net Income USD -283.668 Million - TradingView
Minerva readies 2026 trial for drug aimed at schizophrenia’s ‘negative’ symptoms - Stock Titan
Minerva Neurosciences (NERV) details 2025 loss and new Phase 3 plan after FDA setback - Stock Titan
[144] Minerva Neurosciences, Inc. SEC Filing - Stock Titan
NERV SEC FilingsMinerva Neurosci 10-K, 10-Q, 8-K Forms - Stock Titan
Minerva Neurosciences to Participate in The Citizens Life Sciences Conference - The Manila Times
Biotech CEO to present CNS disorder therapies at Miami conference - Stock Titan
Fed Meeting: Can Minerva Neurosciences Inc continue delivering strong returnsQuarterly Earnings Report & Proven Capital Preservation Tips - baoquankhu1.vn
Minerva Neurosciences (NASDAQ:NERV) Upgraded to Hold at Wall Street Zen - MarketBeat
Is Minerva Neurosciences Inc. in a consolidation phaseMarket Weekly Review & Risk Controlled Swing Alerts - mfd.ru
Minerva Neurosciences (NASDAQ:NERV) Shares Pass Above 50 Day Moving AverageHere's What Happened - MarketBeat
Weekly Earnings: Can Minerva Neurosciences Inc be recession proofTrade Risk Summary & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Is Minerva Neurosciences Inc. stock showing strong momentumGold Moves & Fast Moving Trade Plans - mfd.ru
Balyasny Asset Management L.P. Acquires Significant Stake in Min - GuruFocus
Balyasny Asset Management L.P. Acquires Significant Stake in Minerva Neurosciences Inc. - GuruFocus
Minerva Neurosciences Inc expected to post a loss of 30 cents a shareEarnings Preview - TradingView
Coastlands (NASDAQ: NERV) reports 9.99% stake via convertible preferred/warrants - Stock Titan
Is Minerva Neurosciences Inc. in a long term uptrendTake Profit & Safe Entry Zone Tips - mfd.ru
Aug Swings: What drives MODVs stock priceJuly 2025 Earnings & Accurate Intraday Trading Signals - baoquankhu1.vn
Balyasny discloses 4.33M-share Minerva Neurosciences (NERV) position - Stock Titan
Is Minerva Neurosciences Inc. stock attractive for growth ETFs2025 Growth vs Value & Accurate Buy Signal Notifications - mfd.ru
Minerva Neurosciences (NERV) to Release Earnings on Tuesday - MarketBeat
Minerva Neurosciences, Inc.'s (NASDAQ:NERV) market cap touched US$271m last week, benefiting both retail investors who own 55% as well as institutions - simplywall.st
Institutions profited after Minerva Neurosciences, Inc.'s (NASDAQ:NERV) market cap rose US$27m last week but individual investors profited the most - Yahoo Finance
Will Minerva Neurosciences Inc. (4MNA) stock see valuation expansionWeekly Trend Recap & Proven Capital Preservation Tips - mfd.ru
Minerva Neurosciences Inc (NERV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Minerva Neurosciences (NASDAQ:NERV) Stock Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat
Minerva Neurosciences Expands Board Amid Fundraising Effort - MSN
Market Wrap: Can Minerva Neurosciences Inc continue delivering strong returnsLayoff News & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Analysts Have Conflicting Sentiments on These Healthcare Companies: Minerva Neurosciences (NERV) and Verastem (VSTM) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Minerva Neurosciences (NERV), Gossamer Bio (GOSS) and Merck & Company (MRK) - The Globe and Mail
How Minerva Neurosciences Inc. (4MNA) stock valuation compares with sectorWeekly Investment Summary & Scalable Portfolio Growth Methods - mfd.ru
1.20%
0.06%
자본화:
|
볼륨(24시간):